Airey, N. D., Hammersley, R., and Reid, M. (2020). Schizotypy but not cannabis use modestly predicts psychotogenic experiences: A cross-sectional study using the Oxford–Liverpool Inventory of Feelings and Experiences (O-LIFE). J Addict, 2020, 5961275.Google Scholar

Albert, N., Glenthoj, L. B., Melau, M., et al. (2017). Course of illness in a sample of patients diagnosed with a schizotypal disorder and treated in a specialized early intervention setting. Findings from the 3.5 year follow-up of the OPUS II study. Schizophr Res, 182, 24–30.Google Scholar

Albertella, L., Le Pelley, M. E., Yucel, M., et al. (2018). Age moderates the association between frequent cannabis use and negative schizotypy over time. Addict Behav, 87, 183–189.Google Scholar

Auther, A. M., Cadenhead, K. S., Carrion, R. E., et al. (2015). Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample. Acta Psychiatr Scand, 132, 60–68.Google Scholar

Auther, A. M., McLaughlin, D., Carrion, R. E., et al. (2012). Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. Psychol Med, 42, 2485–2497.Google Scholar

Brooks, G. A., and Brenner, C. A. (2018). Is there a common vulnerability in cannabis phenomenology and schizotypy? The role of the N170 ERP. Schizophr Res, 197, 444–450.Google Scholar

Carney, R., Cotter, J., Firth, J., et al. (2017). Cannabis use and symptom severity in individuals at ultra high risk for psychosis: A meta-analysis. Acta Psychiatr Scand, 136, 5–15.CrossRefGoogle ScholarPubMed

Castle, D. J., and Buckley, P. F. (2015). Schizophrenia, 2nd ed. Oxford: Oxford University Press.CrossRefGoogle ScholarPubMed

Chapman, L. J., Chapman, J. P., and Raulin, M. L. (1976). Scales for physical and social anhedonia. J Abnorm Psychol, 85, 374–382.Google Scholar

Claridge, G. (1994). Single indicator of risk for schizophrenia: probable fact or likely myth? Schizophr Bull, 20, 151–168.CrossRefGoogle ScholarPubMed

Claridge, G., and Broks, P. (1984). Schizotypy and hemisphere function—I: Theoretical considerations and the measurement of schizotypy. Pers Individ Differ, 5, 633–648.CrossRefGoogle Scholar

D’Souza, D. C., Radhakrishnan, R., Naganawa, M., et al. (2021). Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Mol Psychiatry, 26, 3192–3200.Google Scholar

Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry, 6, 427–436.Google Scholar

Eckblad, M., and Chapman, L. J. (1983). Magical ideation as an indicator of schizotypy. J Consult Clin Psychol, 51, 215–225.Google Scholar

Eysenck, H. J. (1992). The definition and measurement of psychoticism. Pers Individ Differ, 13, 757–785.CrossRefGoogle Scholar

Fergusson, D. M., Horwood, L. J., and Swain-Campbell, N. R. (2003). Cannabis dependence and psychotic symptoms in young people. Psychol Med, 33, 15–21.Google Scholar

Freeman, A. M., Mokrysz, C., Hindocha, C., et al. (2021). Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis. J Psychopharmacol, 35, 804–813.Google Scholar

Gage, S. H., Jones, H. J., Burgess, S., et al. (2017). Assessing causality in associations between cannabis use and schizophrenia risk: A two-sample Mendelian randomization study. Psychol Med, 47, 971–980.Google Scholar

Ganesh, S., Cortes-Briones, J., Ranganathan, M., et al. (2020). Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol: A mega analysis of individual participant-data from human laboratory studies. Int J Neuropsychopharmacol, 23, 559–570.CrossRefGoogle ScholarPubMed

Genetic Risk and Outcome in Psychosis (GROUP) Investigators. (2011). Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: An analysis of patient-sibling and sibling-control pairs. Arch Gen Psychiatry, 68, 138–147.Google Scholar

Giordano, G. N., Ohlsson, H., Sundquist, K., et al. (2015). The association between cannabis abuse and subsequent schizophrenia: A Swedish national co-relative control study. Psychol Med, 45, 407–414.Google Scholar

Griffith-Lendering, M. F., Wigman, J. T., Prince van Leeuwen, A., et al. (2013). Cannabis use and vulnerability for psychosis in early adolescence: A TRAILS study. Addiction, 108, 733–740.Google Scholar

Guloksuz, S., Pries, L. K., Delespaul, P., et al. (2019). Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: Results from the EUGEI study. World Psychiatry, 18, 173–182.Google Scholar

Hindley, G., Beck, K., Borgan, F., et al. (2020). Psychiatric symptoms caused by cannabis constituents: A systematic review and meta-analysis. Lancet Psychiatry, 7, 344–353.Google Scholar

Hjorthoj, C., Albert, N., and Nordentoft, M. (2018). Association of substance use disorders with conversion from schizotypal disorder to schizophrenia. JAMA Psychiatry, 75, 733–739.Google Scholar

Johns, L. C., Cannon, M., Singleton, N., et al. (2004). Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry, 185, 298–305.CrossRefGoogle ScholarPubMed

Johnson, E. C., Hatoum, A. S., Deak, J. D., et al. (2021). The relationship between cannabis and schizophrenia: A genetically informed perspective. Addiction, 116, 3227–3234.Google Scholar

Kendler, K. S., Lieberman, J. A., and Walsh, D. (1989). The structured interview for schizotypy (SIS): A preliminary report. Schizophr Bull, 15, 559–571.Google Scholar

Kraan, T., Velthorst, E., Koenders, L., et al. (2016). Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med, 46, 673–681.Google Scholar

Kuepper, R., Ceccarini, J., Lataster, J., et al. (2013). Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLoS ONE, 8, e70378.Google Scholar

Linscott, R. J., and van Os, J. (2013). An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: On the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med, 43, 1133–1149.Google Scholar

Marconi, A., Di Forti, M., Lewis, C. M., et al. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull, 42, 1262–1269.CrossRefGoogle ScholarPubMed

Mason, O., and Claridge, G. (2006). The Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE): Further description and extended norms. Schizophr Res, 82, 203–211.Google Scholar

McHugh, M. J., McGorry, P. D., Yung, A. R., et al. (2017). Cannabis-induced attenuated psychotic symptoms: Implications for prognosis in young people at ultra-high risk for psychosis. Psychol Med, 47, 616–626.Google Scholar

Meehl, P. E. (1962). Schizotaxia, schizotypy, schizophrenia. Am Psychologist, 17, 827–838.Google Scholar

Minor, K. S., Firmin, R. L., Bonfils, K. A., et al. (2014). Predicting creativity: The role of psychometric schizotypy and cannabis use in divergent thinking. Psychiatry Res, 220, 205–210.Google Scholar

Myin-Germeys, I., Krabbendam, L., Delespaul, P., et al. (2003). The affective pathway to psychosis. Schizophr Res, 60, 47.Google Scholar

Nordentoft, M., Thorup, A., Petersen, L., et al. (2006). Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res, 83, 29–40.Google Scholar

O’Tuathaigh, C. M. P., Dawes, C., Bickerdike, A., et al. (2020). Does cannabis use predict psychometric schizotypy via aberrant salience? Schizophr Res, 220, 194–200.Google Scholar

van Os, J., Bak, M., Hanssen, M., et al. (2002). Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol, 156, 319–327.Google Scholar

van Os, J., Hanssen, M., Bijl, R. V., et al. (2000). Strauss (1969) revisited: A psychosis continuum in the general population? Schizophr Res, 45, 11–20.Google Scholar

van Os, J., Pries, L. K., Ten Have, M., et al. (2021). Schizophrenia and the environment: Within-person analyses may be required to yield evidence of unconfounded and causal association: The example of cannabis and psychosis. Schizophr Bull, 47, 594–603.Google Scholar

Parnas, J., Raballo, A., Handest, P., et al. (2011). Self-experience in the early phases of schizophrenia: 5-year follow-up of the Copenhagen Prodromal Study. World Psychiatry, 10, 200–204.Google Scholar

Pasman, J. A., Verweij, K. J. H., Gerring, Z., et al. (2018). GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nat Neurosci, 21, 1161–1170.Google Scholar

Pearson, J. S., and Kley, I. B. (1957). On the application of genetic expectancies as age-specific base rates in the study of human behavior disorders. Psychol Bull, 54, 406–420.Google Scholar

Pries, L. K., Guloksuz, S., Ten Have, M., et al. (2018). Evidence that environmental and familial risks for psychosis additively impact a multidimensional subthreshold psychosis syndrome. Schizophr Bull, 44, 710–719.Google Scholar

Quattrone, D., Reininghaus, U., Richards, A. L., et al. (2021). The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: Findings from the EU-GEI study. Transl Psychiatry, 11, 423.Google Scholar

Radhakrishnan, R., Addy, P. H., Sewell, R. A., et al. (2014a). Cannabis, cannabinoids, and the association with psychosis. In Madras, B., and Kuhar, M. (eds.), The Effects of Drug Abuse on the Human Nervous System (pp. 423–458). Amsterdam: Academic Press.CrossRefGoogle Scholar

Radhakrishnan, R., Guloksuz, S., Ten Have, M., et al. (2019). Interaction between environmental and familial affective risk impacts psychosis admixture in states of affective dysregulation. Psychol Med, 49, 1879–1889.Google Scholar

Radhakrishnan, R., Pries, L-K., Erzin, G., et al. Bidirectional relationships between cannabis use, anxiety and depressive symptoms in mediation of the association with psychotic experience: further support for an affective pathway to psychosis. Psychol Med, 1–7 doi: 10.1017/S0033291722002756 (Online ahead of print).Google Scholar

Radhakrishnan, R., Skosnik, P. D., Ranganathan, M., et al. (2021). In vivo evidence of lower synaptic vesicle density in schizophrenia. Mol Psychiatry, 26, 7690–7698.CrossRefGoogle ScholarPubMed

Radhakrishnan, R., Wilkinson, S. T., and D’Souza, D. C. (2014b). Gone to pot: A review of the association between cannabis and psychosis. Front Psychiatry, 5, 54.Google Scholar

Rado, S. (1953). Dynamics and classification of disordered behavior. Am J Psychiatry, 110, 406–416.Google Scholar

Raine, A. (1991). The SPQ: A scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull, 17, 555–564.Google Scholar

Raine, A. (2006). Schizotypal personality: Neurodevelopmental and psychosocial trajectories. Annu Rev Clin Psychol, 2, 291–326.Google Scholar

Reininghaus, U., Rauschenberg, C., Ten Have, M., et al. (2019). Reasoning bias, working memory performance and a transdiagnostic phenotype of affective disturbances and psychotic experiences in the general population. Psychol Med, 49, 1799–1809.Google Scholar

Schafer, G., Feilding, A., Morgan, C. J., et al. (2012). Investigating the interaction between schizotypy, divergent thinking and cannabis use. Conscious Cogn, 21, 292–298.Google Scholar

Stefanis, N. C., Hanssen, M., Smirnis, N. K., et al. (2002). Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med, 32, 347–358.Google Scholar

Szoke, A., Galliot, A. M., Richard, J. R., et al. (2014). Association between cannabis use and schizotypal dimensions: A meta-analysis of cross-sectional studies. Psychiatry Res, 219, 58–66.Google Scholar

Vadhan, N. P., Corcoran, C. M., Bedi, G., et al. (2017). Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study. Psychiatry Res, 257, 372–374.Google Scholar

Valmaggia, L. R., Day, F. L., Jones, C., et al. (2014). Cannabis use and transition to psychosis in people at ultra-high risk. Psychol Med, 44, 2503–2512.Google Scholar

Vaucher, J., Keating, B. J., Lasserre, A. M., et al. (2018). Cannabis use and risk of schizophrenia: A Mendelian randomization study. Mol Psychiatry, 23, 1287–1292.Google Scholar

Verdoux, H., Sorbara, F., Gindre, C., et al. (2003). Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. Schizophr Res, 59, 77–84.Google Scholar

Verweij, K. J., Abdellaoui, A., Nivard, M. G., et al. (2017). Short communication: Genetic association between schizophrenia and cannabis use. Drug Alcohol Depend, 171, 117–121.CrossRefGoogle ScholarPubMed

Wuthrich, V. M., and Bates, T. C. (2006). Confirmatory factor analysis of the three-factor structure of the schizotypal personality questionnaire and Chapman schizotypy scales. J Pers Assess, 87, 292–304.Google Scholar

Agrawal, A., and Lynskey, M. T. (2014). Cannabis controversies: How genetics can inform the study of comorbidity. Addiction, 109, 360–370.Google Scholar

Andréasson, S., Engström, A., Allebeck, P., et al. (1987). Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet, 330, 1483–1486.CrossRefGoogle Scholar

Archie, S., Boydell, K. M., Stasiulis, E., et al. (2013). Reflections of young people who have had a first episode of psychosis: What attracted them to use alcohol and illicit drugs? Early Interv Psychiatry, 7, 193–199.Google Scholar

Arendt, M., Mortensen, P. B., Rosenberg, R., et al. (2008). Familial predisposition for psychiatric disorder. Arch Gen Psychiatry, 65, 1269.Google Scholar

Arseneault, L., Cannon, M., Poulton, R., et al. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ, 325, 1212–1213.Google Scholar

Baselmans, B. M. L., Yengo, L., Van Rheenen, W., et al. (2021). Risk in relatives, heritability, SNP-based heritability, and genetic correlations in psychiatric disorders: A review. Biol Psychiatry, 89, 11–19.Google Scholar

Bersani, G., Orlandi, V., Kotzalidis, G. D., et al. (2002). Cannabis and schizophrenia: Impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci, 252, 86–92.Google Scholar

Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35, 764–774.Google Scholar

Black, N., Stockings, E., Campbell, G., et al. (2019). Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis. Lancet Psychiatry, 6, 995–1010.CrossRefGoogle ScholarPubMed

Boydell, J., Dean, K., Dutta, R., et al. (2007). A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis. Schizophr Res, 93, 203–210.Google Scholar

Caspi, A., Moffitt, T. E., Cannon, M., et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorhpism in the cathecol-O-methiltransferase gene: Longitudinal evidence of a gene x environment interaction. Biol Psychiatry, 57, 1117–1127.Google Scholar

Colizzi, M., Carra, E., Fraietta, S., et al. (2016). Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr Res, 170, 311–317.Google Scholar

Di Forti, M., Iyegbe, C., Sallis, H., et al. (2012). Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry, 72, 811–816.Google Scholar

Di Forti, M., Marconi, A., Carra, E., et al. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry, 2, 233–238.CrossRefGoogle ScholarPubMed

Di Forti, M., Morgan, C., Dazzan, P., et al. (2009). High-potency cannabis and the risk of psychosis. Br J Psychiatry, 195, 488–491.CrossRefGoogle ScholarPubMed

Di Forti, M., and Murray, R. M. (2005). Cannabis consumption and risk of developing schizophrenia: Myth or reality? Epidemiol Psychiatric Sci, 14, 184–187.CrossRefGoogle ScholarPubMed

Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019a). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry, 6, 427–436.Google Scholar

Di Forti, M., Sallis, H., Allegri, F., et al. (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull, 40, 1509–1517.Google Scholar

Di Forti, M., Wu-Choi, B., Quattrone, D., et al. (2019b). The Independent and Combined Influence of Schizophrenia Polygenic Risk Score and Heavy Cannabis Use on Risk for Psychotic Disorder: A Case-Control Analysis from the EUGEI Study. Cold Spring Harbor Laboratory.Google Scholar

Dragt, S., Nieman, D. H., Schultze-Lutter, F., et al. (2012). Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand, 125, 45–53.Google Scholar

Elkrief, L., Lin, B., Marchi, M., et al. (2021). Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: Testing gene × environment moderation and mediation. Psychol Med, 1–11.Google Scholar

Englund, A., Morrison, P. D., Nottage, J., et al. (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol, 27, 19–27.Google Scholar

Ferdinand, R. F., Sondeijker, F., Van Der Ende, J., et al. (2005). Cannabis use predicts future psychotic symptoms, and vice versa. Addiction, 100, 612–618.Google Scholar

Ferraro, L., La Cascia, C., La Barbera, D., et al. (2021). The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study. Schizophr Res, 236, 69–79.Google Scholar

Ferraro, L., La Cascia, C., Quattrone, D., et al. (2020). Premorbid adjustment and IQ in patients with first-episode psychosis: A multisite case-control study of their relationship with cannabis use. Schizophr Bull, 46, 517–529.CrossRefGoogle ScholarPubMed

Ferraro, L., Russo, M., O’Connor, J., et al. (2013). Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res, 150, 129–135.Google Scholar

Freeman, T. P., Craft, S., Wilson, J., et al. (2021). Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: Systematic review and meta-analysis. Addiction, 116, 1000–1010.Google Scholar

Genetic Risk and Outcome in Psychosis (GROUP) Investigators. (2011). Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: An analysis of patient-sibling and sibling-control pairs. Arch Gen Psychiatry, 68, 138–147.Google Scholar

Gillespie, N. A., and Kendler, K. S. (2021). Use of genetically informed methods to clarify the nature of the association between cannabis use and risk for schizophrenia. JAMA Psychiatry, 78, 467–468.Google Scholar

Giordano, G. N., Ohlsson, H., Sundquist, K., et al. (2015). The association between cannabis abuse and subsequent schizophrenia: A Swedish national co-relative control study. Psychol Med, 45, 407–414.Google Scholar

Gonçalves‐Pinho, M., Bragança, M., and Freitas, A. (2020). Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysis. Int J Methods Psychiatr Res, 29, e1813.Google Scholar

Goodman, S., Wadsworth, E., Leos-Toro, C., et al. (2020). Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets. Int J Drug Policy, 76, 102658.Google Scholar

Guloksuz, S., Pries, L. K., Delespaul, P., et al. (2019). Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: Results from the EUGEI study. World Psychiatry, 18, 173–182.CrossRefGoogle ScholarPubMed

Harley, M., Kelleher, I., Clarke, M., et al. (2010). Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med, 40, 1627–1634.CrossRefGoogle ScholarPubMed

Henquet, C., Di Forti, M., Morrison, P., et al. (2008). Gene–environment interplay between cannabis and psychosis. Schizophr Bull, 34, 1111–1121.Google Scholar

Henquet, C., Murray, R., Linszen, D., et al. (2005). The environment and schizophrenia: The role of cannabis use. Schizophr Bull, 31, 608–612.Google Scholar

Hindocha, C., Quattrone, D., Freeman, T. P., et al. (2020). Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users? Transl Psychiatry, 10, 143.Google Scholar

Hjorthøj, C., Larsen, M. O., Starzer, M. S. K., et al. (2021a). Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016. Psychol Med, 51, 617–622.Google Scholar

Hjorthøj, C., Uddin, M. J., Wimberley, T., et al. (2021b). No evidence of associations between genetic liability for schizophrenia and development of cannabis use disorder. Psychol Med, 51, 479–484.Google Scholar

Houston, J. E., Murphy, J., Adamson, G., et al. (2008). Childhood sexual abuse, early cannabis use, and psychosis: Testing an interaction model based on the National Comorbidity Survey. Schizophr Bull, 34, 580–585.Google Scholar

Jones, H. J., Hammerton, G., Mccloud, T., et al. (2020). Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence. Psychol Med, 1–8.Google Scholar

Kendler, K. S., Ohlsson, H., Sundquist, J., et al. (2019). Prediction of onset of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. Am J Psychiatry, 176, 711–719.Google Scholar

Kolliakou, A., Joseph, C., Ismail, K., et al. (2011). Why do patients with psychosis use cannabis and are they ready to change their use? Int J Dev Neurosci, 29, 335–346.Google Scholar

Large, M., Sharma, S., Compton, M. T., et al. (2011). Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Arch Gen Psychiatry, 68, 555–561.Google Scholar

Marconi, A., Di Forti, M., Lewis, C. M., et al. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull, 42, 1262–1269.Google Scholar

McGuire, P. K., Jones, P., Harvey, I., et al. (1995). Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res, 15, 277–281.Google Scholar

Morgan, C. J. A., Freeman, T. P., Powell, J., et al. (2016). AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Translat Psychiatry, 6, e738–e738.Google Scholar

Murray, R. M., Bhavsar, V., Tripoli, G., et al. (2017a). 30 Years on: How the neurodevelopmental hypothesis of schizophrenia morphed into the developmental risk factor model of psychosis. Schizophr Bull, 43, 1190–1196.Google Scholar

Murray, R. M., Englund, A., Abi-Dargham, A., et al. (2017b). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89–104.Google Scholar

Murray, R. M., and Lewis, S. W. (1987). Is schizophrenia a neurodevelopmental disorder? BMJ, 295, 681–682.Google Scholar

van Os, J., Bak, M., Hanssen, M., et al. (2002). Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiology, 156, 319–327.Google Scholar

van Os, J., Kenis, G., and Rutten, B. P. F. (2010). The environment and schizophrenia. Nature, 468, 203–212.Google Scholar

Potter, D. J., Clark, P., and Brown, M. B. (2008). Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: Implications for psychoactivity and pharmacology. J Forensic Sci, 53, 90–94.Google Scholar

Potter, D. J., Hammond, K., Tuffnell, S., et al. (2018). Potency of Delta(9) -tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. Drug Test Anal, 10, 628–635.Google Scholar

Power, R. A., Verweij, K. J., Zuhair, M., et al. (2014). Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry, 19, 1201–1204.Google Scholar

Quattrone, D., Ferraro, L., Tripoli, G., et al. (2020). Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study. Psychol Med, 51, 1–9.Google Scholar

Quattrone, D., Reininghaus, U., Richards, A. L., et al. (2021). The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. Transl Psychiatry, 11, 423.Google Scholar

Radhakrishnan, R., Wilkinson, S. T., and D’Souza, D. C. (2014). Gone to pot: A review of the association between cannabis and psychosis. Front Psychiatry, 5, 54.Google Scholar

Ruiz-Veguilla, M., Callado, L. F., and Ferrin, M. (2012). Neurological soft signs in patients with psychosis and cannabis abuse: A systematic review and meta-analysis of paradox. Curr Pharm Des, 18, 5156–5164.CrossRefGoogle ScholarPubMed

Schaefer, J. D., Jang, S. K., Vrieze, S., et al. (2021). Adolescent cannabis use and adult psychoticism: A longitudinal co-twin control analysis using data from two cohorts. J Abnorm Psychol, 130, 691–701.Google Scholar

Schoeler, T., Petros, N., Di Forti, M., et al. (2016). Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: An observational study. Lancet Psychiatry, 3, 947–953.Google Scholar

Schoeler, T., Petros, N., Di Forti, M., et al. (2017). Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: A prospective analysis. Lancet Psychiatry, 4, 627–633.Google Scholar

Sideli, L., Fisher, H. L., Murray, R. M., et al. (2018). Interaction between cannabis consumption and childhood abuse in psychotic disorders: Preliminary findings on the role of different patterns of cannabis use. Early Interv Psychiatry, 12, 135–142.Google Scholar

Sideli, L., Quigley, H., La Cascia, C., et al. (2020). Cannabis use and the risk for psychosis and affective disorders. J Dual Diagn, 16, 22–42.Google Scholar

Sideli, L., Trotta, G., Spinazzola, E., et al. (2021). Adverse effects of heavy cannabis use: Even plants can harm the brain. Pain, 162, S97–S104.Google Scholar

Smith, N. (2005). High potency cannabis: The forgotten variable. Addiction, 100, 1558–1560.Google Scholar

Stefanis, N. C., Dragovic, M., Power, B. D., et al. (2013). Age at initiation of cannabis use predicts age at onset of psychosis: The 7- to 8-year trend. Schizophr Bull, 39, 251–254.Google Scholar

Urban, N. B. L., Slifstein, M., Thompson, J. L., et al. (2012). Dopamine release in chronic cannabis users: A [11C]Raclopride positron emission tomography study. Biol Psychiatry, 71, 677–683.Google Scholar

Van Winkel, R., Van Beveren, N. J. M., and Simons, C. (2011). AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology, 36, 2529–2537.Google Scholar

Volkow, N. D., Wang, G. J., Telang, F., et al. (2014). Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci, 111, E3149–E3156.Google Scholar

Wainberg, M., Jacobs, G. R., Di Forti, M., et al. (2021). Cannabis, schizophrenia genetic risk, and psychotic experiences: A cross-sectional study of 109,308 participants from the UK Biobank. Transl Psychiatry, 11, 211.CrossRefGoogle ScholarPubMed

Zammit, S. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ, 325, 1199.Google Scholar

Zammit, S., Moore, T. H. M., Lingford-Hughes, A., et al. (2008). Effects of cannabis use on outcomes of psychotic disorders: Systematic review. Br J Psychiatry, 193, 357–363.Google Scholar

Zammit, S., Spurlock, G., Williams, H., et al. (2007). Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: Interactions with tobacco and cannabis use. Br J Psychiatry, 191, 402–407.Google Scholar

Arendt, M., Rosenberg, R., Foldager, L., et al. (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases. Br J Psychiatry, 187, 510–515.Google Scholar

Asbridge, M., Hayden, J. A., and Cartwright, J. L. (2012). Acute cannabis consumption and motor vehicle collision risk: Systematic review of observational studies and meta-analysis. BMJ, 344, e536.Google Scholar

Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., et al. (2010a). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35, 764–774.Google Scholar

Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., et al. (2010b). Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35, 764–774.Google Scholar

Bloomfield, M. A. P., Hindocha, C., Green, S. F., et al. (2019). The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacol Ther, 195, 132–161.Google Scholar

Böcker, K. B., Hunault, C. C., Gerritsen, J., et al. (2010). Cannabinoid modulations of resting state EEG theta power and working memory are correlated in humans. J Cogn Neurosci, 22, 1906–1916.Google Scholar

Bosker, W. M., Kuypers, K. P., Theunissen, E. L., et al. (2012). Medicinal Δ9‐tetrahydrocannabinol (dronabinol) impairs on‐the‐road driving performance of occasional and heavy cannabis users but is not detected in standard field sobriety tests. Addiction, 107, 1837–1844.Google Scholar

Broyd, S. J., Greenwood, L.-M., Van Hell, H. H., et al. (2016a). Mismatch negativity and P50 sensory gating in abstinent former cannabis users. Neural Plasticity, 2016, 6526437.Google Scholar

Broyd, S. J., Van Hell, H. H., Beale, C., et al. (2016b). Acute and chronic effects of cannabinoids on human cognition: A systematic review. Biol Psychiatry, 79, 557–567.Google Scholar

Chang, L., Yakupov, R., Cloak, C., et al. (2006). Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain, 129, 1096–1112.Google Scholar

Chopra, G. S., and Smith, J. W. (1974). Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry, 30, 24–27.Google Scholar

Cortes-Briones, J., Cahill, J. D., Skosnik, P. D., et al. (2015a). The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans. Biol Psychiatry, 78, 805–13.Google Scholar

Cortes-Briones, J., Skosnik, P. D., Mathalon, D., et al. (2015b). Δ 9-THC disrupts gamma (γ)-band neural oscillations in humans. Neuropsychopharmacology, 40, 2124–2134.Google Scholar

D’Souza, D. C., Abi-Saab, W. M., Madonick, S., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry, 57, 594–608.CrossRefGoogle ScholarPubMed

D’Souza, D. C., Fridberg, D. J., Skosnik, P. D., et al. (2012). Dose-related modulation of event-related potentials to novel and target stimuli by intravenous [delta]9-THC in humans. Neuropsychopharmacology, 37, 1632–1646.Google Scholar

D’Souza, D. C., Perry, E., MacDougall, L., et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558–1572.Google Scholar

Dissanayake, D. W., Zachariou, M., Marsden, C. A., et al. (2008). Auditory gating in rat hippocampus and medial prefrontal cortex: Effect of the cannabinoid agonist WIN55, 212-2. Neuropharmacology, 55, 1397–1404.Google Scholar

Englund, A., Morrison, P. D., Nottage, J., et al. (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol, 27, 19–27.Google Scholar

Freeman, D., Dunn, G., Murray, R. M., et al. (2015). How cannabis causes paranoia: Using the intravenous administration of ∆-9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull, 41, 391–399.CrossRefGoogle ScholarPubMed

Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., et al. (2009a). Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry, 66, 95–105.Google Scholar

Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., et al. (2009b). Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry, 66, 95–105.Google Scholar

Gage, S. H., Jones, H. J., Burgess, S., et al. (2017). Assessing causality in associations between cannabis use and schizophrenia risk: A two-sample Mendelian randomization study. Psychol Med, 47, 971–980.Google Scholar

Ganesh, S., Cortes-Briones, J., Ranganathan, M., et al. (2020). Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol: A mega analysis of individual participant-data from human laboratory studies. Int J Neuropsychopharmacol, 23, 559–570.Google Scholar

Greenwood, L.-M., Broyd, S. J., Croft, R., et al. (2014). Chronic effects of cannabis use on the auditory mismatch negativity. Biol Psychiatry, 75, 449–458.Google Scholar

Greenwood, L.-M., Broyd, S. J., Van Hell, H. H., et al. (2021). Acute effects of Δ9-tetrahydrocannabinol and cannabidiol on auditory mismatch negativity. Psychopharmacology, 239, 1409–1424.Google Scholar

Gupta, S., De Aquino, J. P., D’Souza, D. C., et al. (2019). Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: A responder analysis. Psychopharmacology, 236, 2635–2640.Google Scholar

Helle, S., Løberg, E.-M., Gjestad, R., et al. (2017). The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. Psychiatry Res, 250, 92–98.Google Scholar

Henquet, C., Rosa, A., Krabbendam, L., et al. (2006). An experimental study of catechol-O-methyltransferase Val158Met moderation of Δ-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology, 31, 2748–2757.Google Scholar

Hirst, R., Vaughn, D., Arastu, S., et al. (2021). Female sex as a protective factor in the effects of chronic cannabis use on verbal learning and memory. J Int Neuropsychol Soc, 27, 581–591.Google Scholar

Iseger, T. A., and Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res, 162, 153–161.Google Scholar

Juckel, G., Roser, P., Nadulski, T., et al. (2007). Acute effects of Δ 9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res, 97, 109–117.Google Scholar

Kleinloog, D., Liem-Moolenaar, M., Jacobs, G., et al. (2012). Does olanzapine inhibit the psychomimetic effects of Δ9-tetrahydrocannabinol? J Psychopharmacol, 26, 1307–1316.CrossRefGoogle ScholarPubMed

Kurzthaler, I., Hummer, M., Miller, C., et al. (1999). Effect of cannabis use on cognitive functions and driving ability. J Clin Psychiatry, 60, 395–399.Google Scholar

Liguori, A., Gatto, C. P., and Jarrett, D. B. (2002). Separate and combined effects of marijuana and alcohol on mood, equilibrium and simulated driving. Psychopharmacology, 163, 399–405.Google Scholar

Meier, M. H., Caspi, A., Ambler, A., et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci, 109, E2657–E2664.Google Scholar

Morie, K. P., Wu, J., Potenza, M. N., et al. (2021). Daily cannabis use in adolescents who smoke tobacco is associated with altered late-stage feedback processing: A high-density electrical mapping study. J Psychiatr Res, 139, 82–90.CrossRefGoogle ScholarPubMed

Morrison, P., and Stone, J. (2011). Synthetic delta‐9‐tetrahydrocannabinol elicits schizophrenia‐like negative symptoms which are distinct from sedation. Human Psychopharmacol Clin Exp, 26, 77–80.Google Scholar

Morrison, P., Zois, V., McKeown, D., et al. (2009). The acute effects of synthetic intravenous Δ 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med, 39, 1607–1616.Google Scholar

Murray, R. M., Englund, A., Abi-Dargham, A., et al. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89–104.Google Scholar

Murray, R. M., Mehta, M., and Di Forti, M. (2014). Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis. Biol Psychiatry, 6, 430–431.Google Scholar

Näätänen, R., Paavilainen, P., Rinne, T., et al. (2007). The mismatch negativity (MMN) in basic research of central auditory processing: a review. Clin Neurophysiol, 118, 2544–2590.Google Scholar

Niemi-Pynttäri, J. A., Sund, R., Putkonen, H., et al. (2013). Substance-induced psychoses converting into schizophrenia: A register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry, 74, 20155.Google Scholar

O’Donnell, B. F., and Mackie, K. (2014). The mismatch negativity: A translational probe of auditory processing in cannabis users. Biol Psychiatry, 75, 428–429.Google Scholar

O’Tuathaigh, C. M., Clarke, G., Walsh, J., et al. (2012). Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int J Neuropsychopharmacol, 15, 1331–1342.Google Scholar

Patel, S., Khan, S., Saipavankumar, M., et al. (2020). The association between cannabis use and schizophrenia: Causative or curative? A systematic review. Cureus, 12, e9303.Google Scholar

Patrick, G., and Struve, F. A. (2000). Reduction of auditory P50 gating response in marihuana users: Further supporting data. Clin Electroencephalogr, 31, 88–93.Google Scholar

Pennypacker, S. D., and Romero‐Sandoval, E. A. (2020). CBD and THC: Do they complement each other like yin and yang? Pharmacotherapy, 40, 1152–1165.Google Scholar

Radhakrishnan, R., Skosnik, P. D., Cortes-Briones, J., et al. (2015). GABA deficits enhance the psychotomimetic effects of Δ9-THC. Neuropsychopharmacology, 40, 2047–2056.Google Scholar

Radhakrishnan, R., Wilkinson, S. T., and D’Souza, D. C. (2014). Gone to pot: A review of the association between cannabis and psychosis. Front Psychiatry, 5, 54.Google Scholar

Ranganathan, M., and D’Souza, D. (2006). The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology, 188, 425–444.Google Scholar

Ranganathan, M., De Aquino, J. P., Cortes-Briones, J. A., et al. (2019). Highs and lows of cannabinoid-dopamine interactions: Effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. Psychopharmacology, 236, 3209–3219.Google Scholar

Rentzsch, J., Buntebart, E., Stadelmeier, A., et al. (2011). Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects. Schizophr Res, 130, 222–227.Google Scholar

Roser, P., Della, B., Norra, C., et al. (2010). Auditory mismatch negativity deficits in long-term heavy cannabis users. Eur Arch Psychiatry Clin Neurosci, 260, 491–498.Google Scholar

de la Salle, S., Inyang, L., Impey, D., et al. (2019). Acute separate and combined effects of cannabinoid and nicotinic receptor agonists on MMN-indexed auditory deviance detection in healthy humans. Pharmacol Biochem Behav, 184, 172739.Google Scholar

Schnakenberg Martin, A. M., Bonfils, K. A., Davis, B. J., et al. (2016). Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis. Schizophr Res Cogn, 6, 15–21.Google Scholar

Schnakenberg Martin, A. M., D’Souza, D. C., Newman, S. D., et al. (2021). Differential cognitive performance in females and males with regular cannabis use. J Int Neuropsychol Soc, 27, 570–580.Google Scholar

Seely, K. A., Lapoint, J., Moran, J. H., et al. (2012). Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuro-Psychopharmacol Biol Psychiatry, 39, 234–243.Google Scholar

Sewell, R. A., Schnakenberg, A., Elander, J., et al. (2013). Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology, 226, 401–413.Google Scholar

Sewell, R. A., Skosnik, P. D., Garcia-Sosa, I., et al. (2010). Behavioral, cognitive and psychophysiological effects of cannabinoids: Relevance to psychosis and schizophrenia. Revista Brasileira de Psiquiatria, 32, 515–530.Google Scholar

Sherif, M., Radhakrishnan, R., D’Souza, D. C., et al. (2016). Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry, 79, 526–538.Google Scholar

Skosnik, P. D., Cortes-Briones, J. A., and Hajós, M. (2016). It’s all in the rhythm: The role of cannabinoids in neural oscillations and psychosis. Biol Psychiatry, 79, 568–577.Google Scholar

Skosnik, P. D., D’Souza, D. C., Steinmetz, A. B., et al. (2012). The effect of chronic cannabinoids on broadband EEG neural oscillations in humans. Neuropsychopharmacology, 37, 2184–2193.Google Scholar

Skosnik, P. D., Hajós, M., Cortes-Briones, J. A., et al. (2018). Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans. Neuropharmacology, 135, 412–423.CrossRefGoogle ScholarPubMed

Skosnik, P. D., Krishnan, G. P., Aydt, E. E., et al. (2006). Psychophysiological evidence of altered neural synchronization in cannabis use: Relationship to schizotypy. Am J Psychiatry, 163, 1798–1805.Google Scholar

Skosnik, P. D., Krishnan, G. P., D’Souza, D. C., et al. (2014). Disrupted gamma-band neural oscillations during coherent motion perception in heavy cannabis users. Neuropsychopharmacology, 39, 3087–3099.Google Scholar

Spaderna, M., Addy, P. H., and D’Souza, D. C. (2013). Spicing things up: Synthetic cannabinoids. Psychopharmacology, 228, 525–540.Google Scholar

Stoller, K., Swanson, G. D., and Bellville, J. W. (1976). Effects on visual tracking of δ9‐tetrahydrocannabinol and pentobarbital. J Clin Pharmacol, 16, 271–275.Google Scholar

Stringer, S., Minică, C., Verweij, K. J., et al. (2016). Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. Transl Psychiatry, 6, e769.Google Scholar

Umbricht, D., Koller, R., Schmid, L., et al. (2003). How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry, 53, 1120–1131.Google Scholar

Vaucher, J., Keating, B. J., Lasserre, A. M., et al. (2018). Cannabis use and risk of schizophrenia: A Mendelian randomization study. Mol Psychiatry, 23, 1287–1292.Google Scholar

Volkow, N. D., Swanson, J. M., Evins, A. E., et al. (2016). Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: A review. JAMA Psychiatry, 73, 292–297.Google Scholar

Weinstein, A., Brickner, O., Lerman, H., et al. (2008). Brain imaging study of the acute effects of Δ9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology, 196, 119–131.Google Scholar

Yang, G. J., Murray, J. D., Repovs, G., et al. (2014). Altered global brain signal in schizophrenia. Proc Natl Acad Sci USA, 111, 7438–7443.Google Scholar